KIDSWELL BIO CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 147 JPY | +2.80% |
|
+9.70% | +9.70% |
Valuation
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 14,487 | 14,930 | 14,460 | 5,633 | 5,633 | - |
| Enterprise Value (EV) 1 | 13,680 | 14,569 | 13,973 | 5,633 | 5,633 | 5,633 |
| P/E ratio | -1.98 x | -14.5 x | -26.5 x | -5.24 x | 204 x | 8.13 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 13.5 x | 15 x | 9.22 x | 2.01 x | 2.09 x | 1.64 x |
| EV / Revenue | 13.5 x | 15 x | 9.22 x | 2.01 x | 2.09 x | 1.64 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | -10,925,318 x | -11,765,066 x | - | - | - | - |
| FCF Yield | -0% | -0% | - | - | - | - |
| Price to Book | 10.1 x | 9.99 x | 9.43 x | 6.65 x | - | - |
| Nbr of stocks (in thousands) | 27,647 | 29,623 | 31,435 | 39,390 | 39,390 | - |
| Reference price 2 | 524.0 | 504.0 | 460.0 | 143.0 | 143.0 | 143.0 |
| Announcement Date | 5/25/20 | 5/13/21 | 5/12/22 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,077 | 996.5 | 1,569 | 2,808 | 2,696 | 3,439 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -1,161 | -969.7 | -919 | -838 | 43 | 574 |
| Operating Margin | -107.8% | -97.31% | -58.57% | -29.84% | 1.59% | 16.69% |
| Earnings before Tax (EBT) | -7,314 | -999 | -533 | - | - | - |
| Net income 1 | -7,316 | -1,001 | -535 | -858 | 23 | 554 |
| Net margin | -679.29% | -100.49% | -34.1% | -30.56% | 0.85% | 16.11% |
| EPS 2 | -264.6 | -34.79 | -17.35 | -27.30 | 0.7000 | 17.60 |
| Free Cash Flow | -1,326 | -1,269 | - | - | - | - |
| FCF margin | -123.12% | -127.34% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 5/25/20 | 5/13/21 | 5/12/22 | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | 807 | 361 | 487 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | -1,326 | -1,269 | - | - | - | - |
| ROE (net income / shareholders' equity) | -512% | -64.7% | -35.4% | -77.6% | - | - |
| ROA (Net income/ Total Assets) | - | -25.8% | -25.6% | -29.8% | - | - |
| Assets 1 | - | 3,886 | 2,089 | 2,879 | - | - |
| Book Value Per Share 2 | 51.70 | 50.40 | 48.80 | 21.50 | - | - |
| Cash Flow per Share | -265.0 | -34.80 | -17.30 | - | - | - |
| Capex | 1.94 | 2 | - | - | - | - |
| Capex / Sales | 0.18% | 0.2% | - | - | - | - |
| Announcement Date | 5/25/20 | 5/13/21 | 5/12/22 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
143
JPY
Average target price
800
JPY
Spread / Average Target
+459.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.70% | 34.19M | |
| +20.17% | 127B | |
| +24.67% | 117B | |
| +25.44% | 27.67B | |
| -17.74% | 20.33B | |
| -15.17% | 16.79B | |
| -15.21% | 15.63B | |
| +11.91% | 14.84B | |
| -47.10% | 14.65B | |
| +54.50% | 14.43B |
- Stock Market
- Equities
- 4584 Stock
- Financials Kidswell Bio Corporation
